Kenvue: B of A Securities maintains a 'Buy' Rating, The Target Price is $25

B of A Securities maintains 'Buy' rating on Kenvue(KVUE).

The target price is $25, compare with $27 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-07-15	B of A Securities	Maintains	Buy	Buy	$25	$27
2025-07-15	Barclays	Maintains	Equal-Weight	Equal-Weight	$22	$23
2025-07-15	Citigroup	Maintains	Neutral	Neutral	$22	$24.5

[Company Profile] Kenvue Inc. was incorporated in Delaware on February 23, 2022. The company is the world’s largest pure-play consumer health company. The company seek to deliver sustainable profitable growth through delivering science-backed innovative products, solutions and experiences centered around consumer health. With a presence in more than 165 countries worldwide and an over 135-year legacy, they are a global leader at the intersection of healthcare and consumer goods.